Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,274 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07333677RecruitingEarly Phase 1
Testing CAR-T therapy for severe graves' disease
This early-phase trial tests a new type of treatment called CAR-T cells (special immune cells made in a lab) to target and calm down the overactive immune system in people with severe Graves' disease that hasn't improved with standard medicines. It may offer a new option for those who have been on treatment for years or have had multiple relapses.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06613217RecruitingPhase 1
Oral PCLX-001 for relapsed or refractory AML
This trial tests an oral drug called PCLX-001 for people with acute myeloid leukemia (AML) that has come back or not responded to previous treatments. The goal is to see if the drug is safe and can help control the leukemia.
Houston, TexasAges 18 years+ - NCT07322263RecruitingPhase 2
Gemcitabine and docetaxel for bladder cancer that returned after BCG
This trial tests a combination of two chemotherapy drugs (gemcitabine and docetaxel) given directly into the bladder to treat high-risk non-muscle-invasive bladder cancer that has come back or not responded to BCG therapy. It's for people who cannot or choose not to have their bladder removed.
Iowa City, IowaAges 18–99 - NCT07319676RecruitingPhase 1/Phase 2
Targeted T-cell therapy for relapsed B-cell lymphoma
This trial tests a new type of cell therapy (CAR T) that targets two markers on lymphoma cells, CD19 and CD22. It is for people with aggressive B-cell lymphoma that has not responded to standard treatments.
Singapore, SingaporeAges 10–80 - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT06663098RecruitingPhase 2
Atezolizumab and chemo again for relapsed small cell lung cancer
This trial tests a combination of a second course of chemotherapy and an immunotherapy drug (atezolizumab) for people with extensive-stage small cell lung cancer that has returned after initial treatment. The goal is to see if re-using these treatments together can help control the cancer again.
Aviano (PN)Ages 18 years+ - NCT07311746RecruitingPhase 1/Phase 2
Study of cladribine, ruxolitinib, and venetoclax for T-PLL
This trial tests a combination of three drugs (cladribine, ruxolitinib, and venetoclax) for people with T-cell prolymphocytic leukemia (T-PLL) that has come back or stopped responding to prior treatment. The goal is to see if this therapy can help control the disease.
Houston, TexasAges 18 years+ - NCT07304154RecruitingPhase 1
Study of KITE-363 for autoimmune nerve diseases
This trial tests a new treatment called KITE-363 for people with certain autoimmune nerve diseases, such as multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy, that have not responded well to standard therapies. The goal is to see if it is safe and effective.
Newport Beach, CaliforniaAges 18–75 - NCT07301164RecruitingEarly Phase 1
BCT301 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell treatment called BCT301 for people with certain autoimmune diseases like lupus or scleroderma that haven't gotten better with standard medicines. It aims to see if this treatment can help control the disease.
BeijingAges 18–80 - NCT07296497Recruiting
Acupuncture for stubborn rosacea: safety and effectiveness
This trial tests whether acupuncture can help people with rosacea that hasn't improved with standard treatments like oral antibiotics or light therapy. If you have persistent redness or flushing that affects your daily life, this study may offer a new option.
Changsha, HunanAges 18–65 - NCT06791460RecruitingPhase 2/Phase 3
A study of two drug combinations for ovarian cancer that came back
This trial tests a common chemotherapy (Pegylated Liposomal Doxorubicin) plus an immunotherapy (Adebrelimab), with or without a bladder medication (Mirabegron), in people whose ovarian cancer has returned after initial treatment. The goal is to see if adding Mirabegron helps the other drugs work better.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07280455Recruiting
Comparing gold vs. steel retainers after braces
This study compares two types of fixed retainers (gold vs. stainless steel) to see which works better after braces are removed. It's for people aged 15–30 who have completed orthodontic treatment and have a well-aligned lower front teeth.
Baghdad, Baghdad GovernorateAges 15–30 - NCT04924868RecruitingPhase 3
Ursodeoxycholic acid to prevent gallstone pancreatitis returning
This trial tests whether ursodeoxycholic acid (a bile medicine) can help prevent complications from gallstone-related acute pancreatitis from coming back after you leave the hospital. It may help reduce repeat problems linked to gallstones, especially after an initial pancreatitis episode.
Santiago de Compostela, A coruñaAges 18 years+ - NCT04794777RecruitingPhase 3
Tests targeted scans and rescue radiation for returning prostate cancer
This trial studies whether a targeted scan (PSMA PET/CT) can help doctors choose the best “salvage” radiation treatment when prostate cancer comes back by PSA blood tests after surgery. It may help some people avoid under- or over-treating the areas where the cancer is returning.
Gothenburg, GöteborgAges 18 years+ - NCT05575882Recruiting
Skin cream trial to prevent relapses in very dry eczema skin
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
Ciudad Autónoma de Buenos Aire, Ciudad Autónoma de Buenos AireAges 6 months–15 years - NCT07261345RecruitingEarly Phase 1
CAR-T cell therapy for hard-to-treat Graves' disease
This early-phase trial tests whether specially engineered immune cells (called CAR-T) can treat Graves' disease that hasn't responded to standard medication. It's for people with active, hard-to-control Graves' who have the TRAb antibody.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07254754RecruitingPhase 2
CAR-T cell therapy for late-relapse aggressive lymphoma
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
A Coruña, A CoruñaAges 18 years+ - NCT07256210RecruitingPhase 2
Donor NK cells to prevent leukemia return after stem cell transplant
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
MoscowAges 1 month–25 years - NCT07257419RecruitingPhase 1
CAR T cells and stem cell transplant for leukemia and lymphoma
This trial tests giving special immune cells (CAR T cells) after a half-matched stem cell transplant. It's for children and young adults with high-risk leukemia or lymphoma that has come back or not responded to treatment.
Memphis, TennesseeAges Up to 21 years - NCT07250087RecruitingPhase 1
Asciminib maintenance after transplant or CAR T for Ph+ALL
This trial tests a pill called asciminib given after a stem cell transplant or CAR T therapy to help prevent relapse in adults with Philadelphia chromosome-positive ALL. It is for people whose cancer is currently in remission.
Tampa, FloridaAges 18 years+ - NCT07242963Recruiting
Study of Shh medulloblastoma with U1 mutation
This study looks at people with a certain type of brain tumor called sonic hedgehog medulloblastoma that has come back or not responded to treatment. Researchers want to learn more about these tumors that have a specific genetic change (U1 mutation), which may help find better treatments in the future.
Houston, TexasAges 3–50 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT07225868Recruiting
Coaching to boost cognitive rehab in MS
This trial tests if coaching in goal-directed behavior can improve cognitive rehabilitation for people with relapsing-remitting or secondary progressive MS. It aims to help patients better manage daily tasks and thinking challenges.
Buffalo, New YorkAges 18–65 - NCT06911333RecruitingPhase 1/Phase 2
A new drug for advanced solid tumors that have stopped responding to treatment
This trial tests a new drug called AD1208 for people with advanced solid tumors that have grown despite previous treatments. The goal is to see if the drug can help where other options no longer work or are not suitable.
Seongnam-si, Gyeonggi-doAges 19 years+
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,274 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.